Methods and materials for the diagnosis of prostate cancers
AssigneeCaldera Health Limited
InventorsJames Douglas WATSON, Clare ELTON, David Rex MUSGRAVE
Life of this patent
Estimating the term…
Abstract
Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject using RNA-seq technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject.
Claims22
A method for detecting the presence of a disorder and/or monitoring the progression of the disease in a subject, comprising:
- (a) determining the relative frequency of expression of at least one RNA biomarker in a biological sample obtained from the subject, wherein the frequency of expression is determined using RNA sequencing;
- and
- (b) comparing the relative frequency of expression of at least one RNA biomarker in the biological sample with a predetermined threshold value, wherein increased or decreased relative frequency of expression of the at least one RNA biomarker in the biological sample indicates the presence of the disorder and/or progression of the disorder in the subject.
A method for monitoring progression of a disorder in a subject, comprising:
- determining the relative frequency of expression of at least one RNA biomarker in a biological sample obtained from the subject at a first time point, and determining the relative frequency of expression of the at least one RNA biomarker in a biological sample obtained from the subject at a second, subsequent, time point, wherein the relative frequency of expression is determined using RNA sequencing;
- and
- (b) comparing the relative frequency of expression of the at least one RNA biomarker in the biological sample with a predetermined threshold value, wherein an increase or decrease in the relative frequency of expression of the at least one RNA biomarker in the biological sample at the second time point compared to at the first time point indicates the progression of the disorder in the subject.
An oligonucleotide primer comprising a sequence selected from the group consisting of:
- SEQ ID NO:
- 76-232 and 293-326, wherein the oligonucleotide primer has a length less than or equal to 30 nucleotides.
An oligonucleotide primer consisting of a sequence selected from the group consisting of:
- SEQ ID NO:
- 76-232 and 293-326.
Dependencies are inferred from the claim text.